Barnett, Anthony H and Mithal, Ambrish and Manassie, Jenny and Jones, Russell and Rattunde, Henning and Woerle, Hans J and Broedl, Uli C (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 2 (5). pp. 369-384. ISSN 22138587. This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDsFull text not available from this repository.
Diabetes is a leading cause of chronic kidney disease (CKD) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macrovascular complications and to slow the progression of CKD. We assessed the efficacy and safety of empagliflozin as an add-on treatment in patients with type 2 diabetes and CKD.
|Additional Information:||This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDs|
|Subjects:||WJ Urogenital system. Urology
WK Endocrine system. Endocrinology
|Divisions:||Ambulatory Care > Diabetes|
|Depositing User:||Sophie Rollason|
|Date Deposited:||26 Jun 2014 08:40|
|Last Modified:||26 Jun 2014 08:40|
Actions (login required)